BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Meeting with Investor Group04-06-2024
04-06-2024
BIOCON LTD. - 532523 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 3031-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of meeting with Analyst/ Institutional Investor31-05-2024
BIOCON LTD. - 532523 - Meeting Conducted With Institutional Investors/ Research Analysts
Meeting conducted with Institutional Investors/ Research Analyst31-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of meeting with Analyst/ Institutional Investor27-05-2024
BIOCON LTD. - 532523 - Intimation Of Schedule Of Meeting With Analyst/Institutional Investor
Intimation of schedule of meeting with analyst/ institutional investor27-05-2024
Biocon Signs Licensing, Supply Deal With South Korea's Handok For Chronic Weight Management Product
Under the agreement Biocon will undertake the development, manufacturing and supply of the drug product, and Handok, a specialty pharmaceutical firm, will be responsible for obtaining regulatory approval and commercialisation in the South Korean market, the company said in a statement.24-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed Press Release titled Biocon Limited signs exclusive licensing and supply deal for the commercialization of Liraglutide in South Korea with Handok Inc.24-05-2024
BIOCON LTD. - 532523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for FY 2023-2423-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication23-05-2024